Bristol-Myers Squibb (NYSE:BMY) received a $49.00 target price from stock analysts at BMO Capital Markets in a research report issued on Monday. The firm currently has a “sell” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target indicates a potential downside of 22.32% from the company’s previous close.
Other research analysts have also recently issued research reports about the company. Credit Suisse Group set a $58.00 target price on Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Wednesday, August 16th. Jefferies Group restated a “buy” rating and issued a $72.00 target price on shares of Bristol-Myers Squibb in a research note on Wednesday, September 27th. Cowen reiterated a “hold” rating and set a $65.00 price objective on shares of Bristol-Myers Squibb in a research note on Tuesday, September 19th. Piper Jaffray Companies reiterated a “hold” rating and set a $60.00 price objective on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Finally, Vetr upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $64.08 price objective for the company in a research note on Thursday, August 17th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $64.93.
Bristol-Myers Squibb (NYSE:BMY) traded up $0.66 on Monday, reaching $63.08. The company had a trading volume of 1,612,797 shares, compared to its average volume of 8,409,975. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47. Bristol-Myers Squibb has a fifty-two week low of $46.01 and a fifty-two week high of $66.10. The company has a market cap of $102,146.62, a price-to-earnings ratio of 21.08, a price-to-earnings-growth ratio of 2.37 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). The firm had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.77 EPS. equities research analysts anticipate that Bristol-Myers Squibb will post 2.99 EPS for the current fiscal year.
In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of the business’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the sale, the executive vice president now owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.23% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in Bristol-Myers Squibb by 0.3% during the second quarter. Vanguard Group Inc. now owns 118,661,690 shares of the biopharmaceutical company’s stock worth $6,611,829,000 after acquiring an additional 333,685 shares during the last quarter. BlackRock Inc. increased its stake in Bristol-Myers Squibb by 2.4% during the second quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock worth $5,541,612,000 after acquiring an additional 2,367,864 shares during the last quarter. State Street Corp increased its stake in Bristol-Myers Squibb by 1.8% during the first quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after acquiring an additional 1,223,457 shares during the last quarter. Dodge & Cox increased its stake in Bristol-Myers Squibb by 1.6% during the second quarter. Dodge & Cox now owns 29,579,461 shares of the biopharmaceutical company’s stock worth $1,648,168,000 after acquiring an additional 459,271 shares during the last quarter. Finally, Jennison Associates LLC increased its stake in Bristol-Myers Squibb by 16.2% during the third quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock worth $1,711,689,000 after acquiring an additional 3,735,453 shares during the last quarter. Institutional investors and hedge funds own 69.82% of the company’s stock.
WARNING: “BMO Capital Markets Reiterates “$49.00” Price Target for Bristol-Myers Squibb (BMY)” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/11/bmo-capital-markets-reiterates-49-00-price-target-for-bristol-myers-squibb-bmy.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.